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This paper discusses the technical dimensions of “quality of care” 
in contraceptive service deliveryin both the Cyclofem Introductory Trial, 
as well as in routine service delivery of other injectables in Indonesia. 
Although the quality of care in the Cyclofem trial was generally accept- 
able, substantial weaknesses in screening, clinical technique, the 
management of side-effects, and knowledge concerning re-injection 
time frames were identified in the provision of injectable contra- 
ceptives in routine service delivery. The findings suggest that in order 
for Cyclofem and other injectables to be delivered in the routine 
program with an adequate standard of care, considerable managerial 
adaptation and strengthening of providers’ technical capabilities 
would be necessary prior to actual introduction. This would include 
providing training and updated technical guidelines concerning both 
Cyclofem and other contraceptives to providers, with an emphasis 
on technical issues including contraceptive indications and con- 
traindications, re-injection timeframes, maintenance of asepsis and 
the management of side-effects. Strengthening the existing management 
information system and logistics systems to facilitate differentiation 
between injectable contraceptives provided by the program so 
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as to ensure sufficient supplies of both contraceptives and associated 
materials such as needles and syringes will also be necessary. 
Keywords: monthly combined injectable contraception; Cyclofem; Indonesia; 
quality of care; family planning; health services delivery 
Introduction 
One of the basic strategies of the Indonesian National Family Planning 
Program is to offer a broad range of appropriate contraceptive options to 
potential users. This strategy was adopted primarily due to the recognition 
of both the socio-cultural as well as demographic variation among Indone- 
sian communities. The intent behind this “cafeteria” approach is to allow 
each couple to choose the most suitable contraceptive method according 
to their individual needs. Since the start of the family planning program 
in 1969, a variety of oral contraceptives, intrauterine devices (IUDs), con- 
doms, injectable contraceptives as well as a major new method, Norplant, 
have been gradually introduced into the program. Since March 1990, the 
National Family Planning Coordinating Board (BKKBN) has also been 
conducting an introductory trial under WHO sponsorship of a once-a- 
month injectable, Cyclofem, for the purpose of assessing the appropriate- 
ness of its addition to the Indonesian program.lm3 
Interest incyclofem arises from the fact that the intrinsic characteristics 
of this monthly injectable, short duration of action, rapid return of ovula- 
tion, more regular bleedingpatterns, andhigh efficacy, make it an especially 
attractive method from the perspective of young, low parity women who 
choose to delay the onset of child-bearing or wish to space the timing of 
births. Focus on young women is a major component of the current strategic 
plan of the Indonesian National Family Planning Program. 
While Cyclofem is attractive in light of the current strategy adopted by 
BKKBN, it has been realized that addition of a new contraceptive method 
into ongoing, large and complex programs has extensive implications for 
program management and quality of care. The difficulty of assuring appro- 
priate standards in service delivery increases with each method added to 
the program, making it mandatory to assess whether appropriate capabili- 
ties are in place before new contraceptive technology is introduced. Realiz- 
ing the importance of the management and quality of care implications 
of new contraceptive technology, BKKBN has conducted health services 
research in conjunction with the introductory trial of Cyclofem. l a 
‘Other dimensions of the study, as well as its basic design and methods, are 
presented in greater detail in the preceding companion piece to this paper “Contra- 
ceptive Introduction and the Management of Choice: The Role of Cyclofem in 
Indonesia” by Simmons et a1.j 
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Materials and Methods 
This research study examined the implications for service delivery of 
adding Cyclofem to the national family planning program. More specifi- 
cally, it used a quality of care framework to assess the managerial and 
organizational adaptations that would be necessary to assure quality of 
care in the introduction of Cyclofem to contraceptive service delivery.“,’ 
This study used a qualitative approach, combining it with secondary 
quantitative data to the extent that these were available. A qualitative 
approach was the methodological tool of inquiry most appropriate for the 
endeavor attempted here because it allowed detailed examination of the 
management process, and a focus on systems oriented interpretations of 
program implementation. 
Data collection consisted of systematic observation of service delivery, 
indepth interviews, and document reviews, and was conducted in three 
provinces, namely, Jakarta, West Java and West Sumatra. Observations 
were conducted in clinics where Cyclofem was being provided in connec- 
tion with the introductory trials, as well as in service delivery settings 
where Cyclofem was not yet available (non-trial health centers). 
The non-trial health centers were selected purposely in each province, 
making an attempt to represent both urban and rural facilities (where 
appropriate) as well as to include health centers with moderate or average 
resources and program performance in contrast to the relatively high 
levels exhibited by the trial health centers. 
In total, 28 service delivery sites were observed, including: 4 clinics 
participating in the introductory trial, 7 non-trial health centers, 4 
community-based health posts and 13 private sector settings including 
both private practices and non-governmental organizations clinics. 
Studying these settings allows us to predict what would happen if 
Cyclofem were introduced in these same delivery contexts. For example, 
the interpersonal and technical quality of care dimension in the provision 
of other forms of contraception and in particular other injectables, enables 
one to predict what will happen with Cyclofem. The characteristics of the 
service delivery system tend to be similar for a variety of contraceptives. If 
asepsis is maintained in the delivery of other injectables or IUDs, for 
example, this provides some ground for anticipating that maintaining 
asepsis in the provision of injectables might be assured as well. 
Service delivery settings in the private sector were also included. An 
attempt was made to conduct observations in both urban and rural areas, 
and with a variety of service providers, including nurses, midwives, and 
doctors. 
The instrument for systemizing and recording the results of observa- 
tions was developed for this study. A key characteristic of the observation 
technique adopted for this study was its focus on clinic sessions as a whole 
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and not solely on individual provider-client interactions. The observation 
instrument emphasized observation of the patterns whereby clients 
moved through the clinic or service delivery setting, attempting to under- 
stand their experience from the time they approached the service delivery 
point to their exit from it. 
Another characteristic of the observation procedure developed was to 
document the detailed interactions between provider and client, focusing 
not only on injectables but on all methods provided during the sessions 
under observation. Individual interactions between providers and clients 
were documented both in terms of the exact verbal exchange between 
them but also in terms of the specific components of service delivery. 
Typically, observations were conducted by at least two researchers, in 
most instances involving both a medical doctor and a social scientist. 
In-depth interviews were conducted with the following types of respon- 
dents: 
1. National leaders; in BKKBN, in the Ministry of Health (MOH), from 
the Indonesian Medical Association, the Indonesian Midwives’ Associ- 
ation, the Association of Obstetricians and Gynecologists, the Indone- 
sian Planned Parenthood Association, the Blue Circle Program; 
2. BKKBN and MOH leaders and program managers at the provincial and 
district level; 
3. Public and private sector providers of services in introductory trial, as 
well as non-trial sites, in urban, semi-urban and rural areas, including 
BKKBN and MOH field staff; 
4. Community leaders as represented by village leaders, their wives in 
their capacity as leaders of the PKK, the formal village women’s group. 
5. Clients, including both Cyclofem acceptors and dropouts in trial areas, 
and users of other iniectables and other methods in non-trial areas. 
Interview guidelines for the various categories of respondents were 
developed to provide a broad outline for the topics to be covered in these 
in-depth conversations. In-depth interviews were conducted by one or 
more members of the research team. 
Results 
This paper presents findings from the study pertaining to the technical 
quality of care, with a focus on the medical and technical standards with 
which contraceptive services are provided. The dimensions of technical 
quality of care considered here include: (a) assessment of indications and 
contraindications; (b) clinical technique, especially whether asepsis is 
maintained in the provision of the “clinical” methods; (c) management 
of side effects; (d) appropriate follow-up in service delivery. 
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Observations of both Cyclofem and other contraceptive service delivery 
were conducted in health centers participating in the Cyclofem introduc- 
tory trial, while observations in non-trial health centers included the 
provision of oral and injectable contraceptives, as well as IUD insertion. 
These observations are discussed below in terms of the various dimen- 
sions of the technical quality of care. 
Assessment of Indications and Contraindications 
In the Cyclofem trial, screening for breast-feeding, an important contrain- 
dication to the use of estrogen-containing contraceptives, was conducted 
consistently. Breast-feeding status was typically assessed by providers 
when women were first queried about their potential interest in joining 
the trial. However, observation of the formal screening process used later 
in the assessment of other indications and contraindications of Cyclofem 
raised several concerns. Appropriate indications, such as the advantages 
of Cyclofem for women wishing to space their children, were not commu- 
nicated to women, although occasionally inappropriate indications such 
as “Cyclofem will make you slender” or “it will help you to gain weight” 
were used in an attempt to persuade women to enter the trial. In contrast, 
a series of questions from the trial protocol checklist enumerating contra- 
indications was conscientiously read to each client during enrollment. 
Although this verbal screening was complete in content, the issue of its 
potential value or efficacy as a screening tool arose due to the medical 
terminology used. It is doubtful that clients were able to fully understand 
the terms used to identify contraindicated conditions. For example, 
women asked if they suffer from “liver disease, cancer, heart disease, or 
thromboembolism” are unlikely to either understand or be able to identify 
the applicability of such terminology to their own condition. 
The process of screening observed in the assessment of indications and 
contraindications for other contraceptives in routine service delivery var- 
ied widely from provider to provider, but typical patterns were noted com- 
mon to both the trial and non-trial health centers. The first question usually 
asked by providers to clients was the date of their last menstrual period so 
as to screen for pregnancy. Most women appeared to know that providers 
typically require a women to be menstruating as a prerequisite for services 
and thus they come for a family planning method at that time. 
The formal screening process is intended to be supported by the use 
of the so called “K-IV” family planning clinic record form which lists 
background information for each client including their identity, their 
reproductive status and desires, and a checklist for the assessment of 
contraindications.8 Direct assessment of indications for the choice of a 
particular contraceptive based on women’s reproductive desires or medical 
history was only occasionally observed. When women were asked about 
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their reproductive intentions, it was usually as a prelude to suggesting 
the use of a long-acting method such as the IUD. Rarely were younger 
clients asked about their needs in regard to a contraceptive suitable for 
spacing. The choice of an appropriate contraceptive depends on a woman’s 
stage in her reproductive life cycle and the K-IV form provides the neces- 
sary information, but providers must make use of this information in 
their assessment. However, this was often not the case. 
The section of the K-IV form to be used in screening for contraceptive 
contraindications is labeled “Screening for Pills”, and the screening ques- 
tions are those appropriate for combined hormonal contraceptives. This 
is surprising as the National Family Planning Program supplies both com- 
bined oral contraceptives, as well as a progestogen-only “mini-pill” for 
breast-feeding women who desire to use an oral contraceptive. Clearly, 
the screening form has not been updated since the introduction of this 
alternative. Perhaps more importantly, the screening checklist provided 
does not present an appropriate list of contraindications for the two 
progestogen-only injectable contraceptives provided by the program. It 
was observed that providers, in general, do not differentiate among the 
various hormonal contraceptives in the screening process, but instead 
utilize the checklist intended for combined oral contraceptives for all 
hormonal contraceptives, including injectables, if and when formal 
screening does occur. This is a clear example of where the addition of new 
contraceptive methods without the appropriate adjustment in technical 
guidelines and directives has resulted in confusion on the part of providers 
and the inability to maintain technical standards of care. 
Moreover, to facilitate the process of screening, an attempt has been 
made in the K-IV form to translate certain medical contraindications into 
symptoms that are readily understood by clients. However, some of the 
symptoms utilized on the form to represent contraindications are so non- 
specific that they may unnecessarily prevent women from using the 
method of their choice. For example, “swollen feet” or “difficulty breath- 
ing” are included as signs of heart disease, but these symptoms are very 
general in nature and may result from a variety of non-contraindicated 
conditions. 
Providers consider a physical exam to check for potential contraindica- 
tions a prerequisite for each client prior to the adoption of a new contracep- 
tive. Some type of physical assessment was observed to be regularly 
conducted. However, these exams were extremely variable in content, 
often consisting of no more than a measurement of the client’s blood 
pressure. Exams also did not focus on the assessment of specific contrain- 
dicated conditions (i.e., liver enlargement) but focused more typically on 
examination for a variety of less sensitive and specific signs. For example, 
sometimes the client’s abdomen would be palpated, but in a manner too 
superficial to detect pregnancy or other potential anomalies. Perhaps the 
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most consistently observed examination for physical signs was an assess- 
ment of varicose veins in the lower extremities. Women with even the 
most minor of superficial varices were often told they could not use a 
hormonal contraceptive. 
The K-IV form is intended to assist the provider in the screening of 
contraindications, while detailed guidance and instructions in the techni- 
cal dimensions of service delivery, including the assessment of indications 
and contraindications for various contraceptives, are contained in the 
BKKBN Medical Handbook for Family Planning.9 A comparison of screen- 
ing criteria provided by the Medical Handbook with the contraindications 
for oral contraceptives on the K-IV form shows that the two are not 
completely congruent. For example, breastfeeding is not mentioned as 
a contraindication for combined oral contraceptives in the K-IV form, 
although most health center providers are aware that it is contraindicated. 
Liver disease, as represented by the symptom of jaundice in the K-IV form 
is not mentioned in the Handbook, although this too is an important 
contraindication for oral contraceptives. Perhaps more important was the 
fact that this medical handbook did not seem to be readily accessible to 
all providers of clinical family planning methods. 
Clearly, the existence of a screening and assessment checklist such 
as the K-IV form does not assure that an appropriate consideration of 
indications and contraindications will take place. Yet, if it is to have 
any impact, it does need to be technically appropriate and to reflect the 
differences in the indications and contraindications specific to individual 
contraceptive methods. The fact that many providers ignored the K-IV 
form may reflect their sense that it is incomplete and inappropriate for 
many of the methods that they provide. However, it was clear from both 
interviews with providers and observations that providers’ knowledge and 
actual practice related to the assessment of the indications and contraindi- 
cations of various contraceptives was weak. The addition of every new 
method that has a slightly different profile of characteristics and contrain- 
dications represents additional potential for confusion and poor care if 
efforts are not made to educate and train providers appropriately. The 
experience with the Cyclofem trial suggests that providers can take the 
time to assess contraindications but steps must be taken to assure that 
screening is effective, rather than either a ritual or a needless barrier to 
hormonal contraceptive use.‘O 
Clinical Technique 
One of the main concerns in clinical technique with regard to contracep- 
tive service delivery is whether or not the maintenance of asepsis is 
assured.” In the provision of injectables, asepsis must be maintained 
through appropriate use of sterilized needles and syringes. We observed 
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consistent one-time use of disposable syringes and needles in the provision 
of Cyclofem. In non-trial health centers, we observed that in the service 
provision of depot-medroxyprogesterone acetate (DMPA) and norethister- 
one enanthate (NET-EN), disposable needles and syringes were also uti- 
lized, but a variety of patterns existed with regard to the maintenance of 
asepsis. In five of the health centers, disposable needles and syringes were 
used once and discarded after use. In a second pattern observed in three 
health centers, providers used the same syringe for five clients, but 
changed to a new sterile needle for each client. In a third pattern followed 
in two health centers and one sub-health center, we observed that one 
syringe and one needle were reused without sterilization for multiple 
acceptors. In all settings, providers routinely used alcohol to swab the 
injection site. In one health center, the cotton was used several times, 
while in all other settings the cotton was used only once. Lack of asepsis 
in provision of injections clearly presents unacceptable risks for transmis- 
sion of hepatitis B which is endemic in Indonesia, as well as the potential 
for HIV transmission once the virus becomes prevalent in the general 
Indonesian population. 
A more general lack of attention to asepsis in contraceptive service 
delivery was also evident. Only rarely were hands washed before providing 
services. Running water (either piped or from a bucket with a spigot) was 
unavailable in the service delivery room in many of the health centers 
and gloves were regularly reused without proper disinfection. IUDs were 
observed to be inserted without adequate sterilization of the insertion 
instruments in several of the settings, and equipment used for pelvic 
exams sometimes received only cursory cleansing between clients. 
Management of Side Effects 
In the Cyclofem trial, information about potential side-effects of the 
method was generally not communicated directly by providers, but was 
provided through distribution of a leaflet. Given the low literacy status 
of many users and the fact that they predominantly speak one of several 
local languages rather than the national Indonesian language used in 
the leaflet, many users would not be able to understand these written 
materials. When discussion of side-effects did occur, it was used more 
frequently as a motivational strategy rather than as a means of providing 
women with balanced information about contraceptive use. For example, 
Cyclofem was promoted to “make your period regular”, “make you slim” 
or “to help you gain weight”. When acceptors were observed to complain 
of potential non-specific side-effects of Cyclofem such as mild aches, pains 
and occasional dizziness, these complaints tended to be automatically 
dismissed by providers as inconsequential and not related to contraceptive 
use. In general, providers did not take the time to assess whether these 
side-effects were actually related to contraceptive use. 
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The two most commonly reported specific side-effects of injectable use 
were amenorrhea and spotting or irregular bleeding. We observed some 
complaints about amenorrhea from Cyclofem users, but DMPA users 
frequently complained of this problem. The first response of the provider 
appears to be to inform the client that this is nothing to worry about, 
and that the amenorrhea is normal. In the interviews, providers stated 
that when amenorrhea persists and the client continues to complain, she 
may be given one or two cycles of oral contraceptives, and then be 
switched back to an injectable after menstruating. Several instances of 
service provision where this was indeed the pattern were observed. When 
DMPA and NET-EN users complained of spotting or heavy bleeding, pro- 
viders made little attempt to distinguish the degree of spotting or bleeding 
or to assess the seriousness of the problem from a medical perspective. 
Moreover, interviews with providers revealed that their knowledge of 
how to address these side effects was limited. 
Follow-up: Windows for Re-injection 
The typical pattern observed with regard to communication with a client 
about when to return for re-injection was to tell the woman to come back 
on a particular date, rather than to inform her of the fact that there is a 
window of several days during which re-injection could occur. This pat- 
tern was the same for all three injectables, DMPA, NET-EN and Cyclofem. 
Almost all providers of Cyclofem appeared to know that there is a window 
of time, 30 plus or minus three days, during which Cyclofem can be 
re-injected. Although some clients knew that there is a time window, 
providers emphasized one particular day as the appropriate time of return 
for re-injection. There was considerable disagreement among providers 
as to the appropriate time window for DMPA re-injection, with the most 
frequently mentioned periods being either 90 days or twelve weeks. This 
difference corresponds to a change in the period recommended in the 
BKKBN technical guidelines which occurred in 1989.9 
The pattern of service delivery for women who come for re-injection 
after the appropriate period of time has elapsed was also variable. Some 
providers reported that they do not give the injectable, even if the woman 
is only a day or two past the recommended date of return. In such cases, 
they switch women to oral contraceptives to await the onset of menstrua- 
tion, or in some instances ask them to wait for their period without 
mentioning the use of another contraceptive. Others reported that they 
inquire about the status of the woman’s menstrual cycle and her recent 
pattern of intercourse to determine whether or not the client might be 
pregnant. If there is no reason to suspect she might be pregnant, the 
injection is provided even though the proper window for re-injection has 
elapsed. 
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The main mechanism used to assure return of injectable users at the 
appropriate time was to write the date on the family planning identifica- 
tion card that each patient keeps. Consistent recording of the return date 
on the card was observed for both Cyclofem and other injectable clients 
and women were frequently reminded twice in the course of service 
delivery to return on the appropriate date. In the Cyclofem trial, a mecha- 
nism has been developed for formal follow-up of women who do not 
return at the appropriate time for their re-injection. This mechanism was 
established for research purposes, however, and there is no regular system 
of follow-up for users of other injectable methods if they fail to return 
for re-injection. Although a variety of approaches to follow-up have been 
established by field-staff in some individua1 health centers, the feasibility 
of these efforts on a more widespread basis is open to question due to a 
variety of personnel, time and other managerial constraints. 
For all practical purposes, women are responsible for remembering the 
date of their return. We found from interviews with clients that they are 
very conscientious of this responsibility, often taking special precautions 
to remember the date. Almost all providers reported that the vast majority 
of clients return on time and that remembering the date does not appear 
to be a problem as women mark their wall calendar, a ubiquitous item 
even in rural households. Providers and clients indicated that Cyclofem 
is even easier to remember than DMPA, both because it is a shorter 30- 
day period and because clients can be told to come on the same date of 
each month. 
Discussion 
Assuring consistency and technical accuracy in the effort to screen for 
contraindications, manage side-effects, maintain proper clinical proce- 
dures, and provide information and follow-up in a large program with 
literally thousands of providers is a major undertaking. We observed that 
under the present system, providers sometimes do not distinguish among 
hormonal contraceptives in the various dimensions of technical quality 
of care. Moreover, it is difficult to keep large numbers of providers, both 
at the health center level and in the decentralized rural delivery system, 
well informed about the changes in technical guidelines which occur over 
time. The changing criteria for technical management resulting from the 
evolution of hormonal contraceptives is one such example. Key manage- 
rial factors which determine or explain the various conditions we observed 
are listed below: 
1. Supply shortages: Chronic shortages of basic equipment and other 
medical supplies are a major reason for the breakdown in technical 
quality of care in the delivery of family planning and other health 
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services. Shortages of syringes and needles are pervasive in the public 
sector health service delivery system and seriously impair the mainte- 
nance of appropriate quality of care in the delivery of injectable contra- 
ceptives. In those health centers where a single needle and syringe 
were used for each client, providers explained that this was possible, 
despite inadequate supplies provided by the program, because clients 
were asked either to buy their own syringe and needle or to pay a small 
charge for the purchase of these supplies. 
2. Staff knowledge and attitudes: Inadequate knowledge of the indications 
and contraindications of specific hormonal and other contraceptives, 
and a lack of appreciation of the importance of asepsis and the necessary 
procedures for its maintenance are key reasons for the inadequacies 
in clinical procedures. Insufficient baseline technical knowledge, lack 
of recent refresher training, and a lack of accessible written guidelines 
or instructions may be important factors resulting in these deficits. 
3. Patient load: Patient loads have a major influence on the extent to 
which sterility of equipment and procedures is assured. If many women 
need services, stocks are quickly exhausted and there is inadequate 
time between patients to assure appropriate disinfection or steriliza- 
tion of equipment. Heavy patient loads may also contribute to provid- 
ers not taking time to systematically screen clients for potential 
contraceptive contraindications or to provide appropriate physical 
exams. 
4. Provider fears and culture of information-giving: As discussed in the 
preceding paper by Simmons et al.” information-giving often does not 
receive much attention in service delivery at the health center. This 
pattern is particularly strong in regard to the discussion of side-effects 
as providers often fear that discussion of potential negative conse- 
quences may be misinterpreted and discourage contraceptive use. 
5. Lack of technical supervision: While administrative supervision is con- 
ducted regularly, the technical dimension of supervision is weak. Staff 
with responsibility for supervision at the district level often lack suffi- 
cient technical expertise and are of lower professional status than the 
physicians in charge of service delivery at the health centers. Thus, 
issues concerning the technical quality of care being delivered are 
rarely reviewed or discussed during supervisory visits. 
6. General lack of attention to the technical dimensions of quality of care: 
In the past, the technical dimensions of quality of care in contraceptive 
service delivery have been de-emphasized in comparison with the at- 
tention given to other objectives of the family planning program. Re- 
cent BKKBN meetings and workshops have begun to address these 
issues, but initial attention has focused more on clinical methods 
including Norplant and IUD insertion and did not include discussion 
of injectable contraceptives.12 
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Program Implications 
The findings presented in this paper document that although some dimen- 
sions of the technical quality of care in contraceptive service delivery in 
the study sites conform to accepted standards, substantial weaknesses in 
the area of screening, clinical technique, the management of side-effects, 
and re-injection time frames were also identified. The technical quality 
of services provided in the context of the Cyclofem introductory trial 
were considerably stronger, but some weaknesses were observed. These 
findings suggest that in order for Cyclofem and other contraceptives to 
be delivered in the routine program with an adequate standard of care, 
considerable managerial adaptation and strengthening of the technical 
capabilities of service providers would be necessary. This is particularly 
evident if one considers that introductory trials are typically conducted 
in facilities chosen to be representative of a relatively high standard of 
service delivery. 
As these findings are based on observations and interviews in a rela- 
tively limited number of study sites, the question must be raised as to 
how generalizable they are for the Indonesian Family Planning Program 
as a whole. While the total number of sites is small, the study included 
four of six health centers participating in the Cyclofem introductory trial. 
These trial centers were purposively selected by BKKBN to represent 
strong program management and service delivery capabilities. Non-trial 
health centers were selected with the assistance of provincial program 
staff to assure representation of both average and relatively weak service 
performance. As a result, a broad range of service delivery capabilities 
were included in this study. The observation of a variety of deficiencies 
in routine service delivery in both the trial and non-trial health centers 
suggest that these problems are likely to be common more widely. It is 
also important to keep in mind that this research is program-based and, 
thus, many of the issues considered are constant throughout the program 
rather than variable between health centers. For example, weaknesses in 
technical guidelines, screening forms, reporting and recording, and logis- 
tics systems are likely to be consistent across the national program. Fur- 
thermore, these observations were acknowledged and confirmed in 
interviews with BKKBN and Ministry of Health officials, and documented 
in other reports.‘” 
While some of the observed weaknesses have undoubtedly existed for 
a long time, many may have become accentuated over the recent years 
as a variety of new contraceptives have been introduced into the routine 
program. For example, changes in the composition and range of hormonal 
contraceptives (including both oral and injectable contraceptives) have 
resulted in the necessity of increasingly complex criteria for assessing 
indications and contraindications, re-injection windows, and logistics 
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necessary to support service delivery and the management of side-effects. 
In contrast, the service delivery system may function best with clear, 
simple rules which can be quickly taught and which are easily understood 
by both the provider and the client. The search for simplicity and routin- 
ized instructions, however, may lead to the use of inappropriate guidelines 
and compromises in the quality of services provided. 
The addition of another hormonal contraceptive method would clearly 
place an additional burden on the existing health service delivery system 
and would predictably imply additional confusion and difficulties in the 
maintenance of the technical quality of care. With specific regard to Cyclo- 
fern, it seems plausible to predict that the same weaknesses in technical 
standards of care that characterize injectable service delivery currently 
would apply to this newly added contraceptive as well. 
On the other hand, one can also view the introduction of Cyclofem as 
an opportunity for a systematic effort to improve the delivery of injectable 
services. While it is true that additional contraceptive technology without 
requisite training and other managerial adaptations would weaken stand- 
ards of care, it can also be argued that with appropriate and systematic 
attention to these issues, significant improvements in overall service 
delivery could be attained. Addition of a new method could provide an 
opportunity to inform staff about the new method and to update them 
on the technical requirements for existing methods. Operational problems 
which currently constitute barriers to the technical quality of care can 
also be addressed in such training. 
If Cyclofem is to be introduced into the family planning program in 
the public sector, a number of managerial adaptations would appear neces- 
sary to achieve and maintain technical quality of care standards. A consid- 
eration of our study findings suggest that the following activities or actions 
would have to be implemented: 
1. Technical guidelines and instructions must be updated and made avail- 
able to all providers. The BKKBN Family Planning Medical Handbook 
must be updated to include information concerning the various techni- 
cal dimensions of service delivery in regard to Cyclofem. In particular, 
Cyclofem must be clearly differentiated from other injectable contra- 
ceptives in regard to its intrinsic characteristics. This handbook should 
be widely distributed to all service delivery points. In addition, an 
abbreviated version summarizing the technical guidelines should be 
distributed to every provider. 
2. Training will have to be provided to all family planning service provid- 
ers in the public sector so as to increase their technical knowledge and 
skills concerning Cyclofem, in general, and, specifically, its differentia- 
tion from other injectables with regard to the various dimensions of 
technical care. 
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3. Written guidelines and other materials should be developed for provid- 
ers in support of the adequate assessment of the indications and contra- 
indications of Cyclofem and other contraceptives. For example, the 
contraceptive screening checklist (K-IV) could be adapted so as to in- 
clude the differing contraindications for each of the available methods. 
Specific necessary components of an appropriate physical screening 
exam should also be included. 
4. A functional system of routine technical support and supervision for 
providers must be established. 
5. The existing management information system reporting forms should 
be revised to differentiate Cyclofem from other injectables so that the 
necessary quantities of needles and syringes can be determined and 
supplied. 
6. The elements of the logistics system related to the supply of both 
needles and syringes, as well as supply of disinfection solution, should 
be reviewed so as to determine how best to assure that one disposable 
needle and syringe be provided for each dose of an injectable contracep- 
tive. 
7. The number of clients receiving service delivery of clinical techniques 
at one place and time should match available staff, the quantity of 
equipment available and the time necessary for disinfection of equip- 
ment prior to reuse. 
Clearly this list of managerial and programmatic adaptations to support 
the introduction of Cyclofem into the national public sector family plan- 
ning program would present a considerable challenge with regard to both 
manpower and the financial resources necessary to support these training 
and logistic requirements. The benefits to the program overall could po- 
tentially be significant, particularly if viewed from the perspective that 
these activities would strengthen the technical quality of care in the 
provision of a variety of contraceptive methods offered in the Indonesian 
program. However, prior to commencing with such introduction, program 
planners must carefully assess whether the advantages offered by the 
introduction of a new method such as Cyclofem justify the managerial 
challenge and the financial burden of proceeding. If introduction is con- 
templated without the managerial adaptations and training discussed 
above, the result is likely to be further confusion on the part of providers 
and a concomitant reduction in the overall level of the technical dimen- 
sions of quality of care in contraceptive service delivery. 
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